NOTE: This video is ONLY available to watch in selected countries and geographies [geoip-content not_country=”US”]
Thomas Zeller (Bad Krozingen, Germany) talks to Vascular News about the iliCo study, of which he is co-principal investigator, and which is designed to evaluate the safety and efficacy of the iCover next-generation stent (iVascular) for the treatment of de novo iliac atherosclerotic lesions in patients with symptomatic arteriopathy of the lower limbs (Rutherford class two to five).
The primary endpoint is target lesion primary patency at 12 months and secondary endpoints include safety at 30 days (all cause death, major adverse events and major local complications), quality of life, as well as rates of target lesion and target vessel revascularisation.
Zeller states that he “expects to see that the device is safe” and that it is “easy to apply because it is a very flexible technology.” In addition, “we know from past studies that stent grafts may improve outcomes in particular in complex lesions,” he adds. This is why enrolment was separated into two groups (TASC A/B lesions and TASC C/D lesions), notes Zeller.
“There is very limited data [on covered stent grafts], at least compared to traditional stent implantation,” says Zeller, adding however that it seems that covered stents “may play an important role in complex lesions”. He concludes by outlining some of the key features of the device, including its “flexibility” and that “you can upsize the stent graft”.
This video is sponsored by iVascular.
[/geoip-content]
